249 related articles for article (PubMed ID: 33262759)
1. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
3. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
5. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
Kasturi SP; Rasheed MAU; Havenar-Daughton C; Pham M; Legere T; Sher ZJ; Kovalenkov Y; Gumber S; Huang JY; Gottardo R; Fulp W; Sato A; Sawant S; Stanfield-Oakley S; Yates N; LaBranche C; Alam SM; Tomaras G; Ferrari G; Montefiori D; Wrammert J; Villinger F; Tomai M; Vasilakos J; Fox CB; Reed SG; Haynes BF; Crotty S; Ahmed R; Pulendran B
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32561559
[TBL] [Abstract][Full Text] [Related]
6. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
Front Immunol; 2018; 9():381. PubMed ID: 29541075
[TBL] [Abstract][Full Text] [Related]
7. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
8. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.
Wille-Reece U; Wu CY; Flynn BJ; Kedl RM; Seder RA
J Immunol; 2005 Jun; 174(12):7676-83. PubMed ID: 15944268
[TBL] [Abstract][Full Text] [Related]
9. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
Dowling DJ
Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
13. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
[TBL] [Abstract][Full Text] [Related]
15. Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice.
Liu R; Wang J; Yang Y; Khan I; Zhu N
Virology; 2016 Oct; 497():102-110. PubMed ID: 27449478
[TBL] [Abstract][Full Text] [Related]
16. TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.
Oh JZ; Kurche JS; Burchill MA; Kedl RM
Blood; 2011 Sep; 118(11):3028-38. PubMed ID: 21813451
[TBL] [Abstract][Full Text] [Related]
17. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.
Gautier G; Humbert M; Deauvieau F; Scuiller M; Hiscott J; Bates EE; Trinchieri G; Caux C; Garrone P
J Exp Med; 2005 May; 201(9):1435-46. PubMed ID: 15851485
[TBL] [Abstract][Full Text] [Related]
18. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
Longhi MP; Trumpfheller C; Idoyaga J; Caskey M; Matos I; Kluger C; Salazar AM; Colonna M; Steinman RM
J Exp Med; 2009 Jul; 206(7):1589-602. PubMed ID: 19564349
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection.
Lebel MÈ; Daudelin JF; Chartrand K; Tarrab E; Kalinke U; Savard P; Labrecque N; Leclerc D; Lamarre A
J Immunol; 2014 Feb; 192(3):1071-8. PubMed ID: 24376264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
